GSK responds to MSF's plea with pricing explanation--no discount

An article from FierceVaccines
April 23, 2015
After urging price concessions for pneumococcal disease vaccines in January and receiving a 20-cent-per-dose discount from Pfizer ($PFE), Médecins Sans Frontières is sure to be unhappy with GlaxoSmithKline's ($GSK) response.
 
The British drugmaker issued a statement on Thursday explaining that the prices of its Synflorix are as low as possible and offered no discount.
 
"Many of our available vaccines are advanced and complex and require significant upfront capital investment to make and supply," the statement said. "Our pneumococcal vaccine is one of the most complex we've ever manufactured, essentially combining 10 vaccines in one."
 
Read more here
Common Disease Taxonomy: 
Common Vaccine Taxonomy: 
0